Live Cell Beating Assay Using Human iPSC-derived Cardiomyocytes for Evaluation of Drug Efficacy and Toxicity
Poster Oct 05, 2011
Oksana Sirenko, Carole Crittenden, Blake Anson, Jayne Hesley, Yen-Wen Chen, Nick Callamaras and Evan F. Cromwell
Derived from human induced pluripotent cells and highly purified, iCell® Cardiomyocytes are especially attractive because they express ion channels and demonstrate beating and action potentials similar to primary cardiac cells.
The work in this poster demonstrates cell based assays for measuring the impact of pharmacological compounds on the rate and magnitude of beating cardiomyocytes with different instrument platforms.
Applications of chemically modified synthetic guide RNA for CRISPR-Cas9 genome editingPoster
Our results indicate that MS modifications are required for experiments with co-electroporation of Cas9 mRNA and synthetic gRNA, yet have no impact on editing efficiency when delivered with lipid-based transfection reagents.READ MORE
Novel lead optimization strategy of BACE I inhibitors for the treatment of Alzheimer’s disease by Quantitative Structure-Activity Relationship (QSAR) and Physiologically-Based Pharmacokinetics (PBPK) modelingPoster
In this study, we introduce an innovative in silico-based high throughput lead optimization strategy with QSAR and PBPK modelings using StarDrop™, ADMET predictor® and GastroPlus®.READ MORE
Use of Non-modified RNAs for the Derivation of Clinically-relevant iPS Cell Lines from Human Blood, Urine and Skin Cells using GMP-compliant ReagentsPoster
We have developed protocols using our StemRNA-NM Reprogramming Kit for generating iPS cells from skin-derived fibroblasts, blood-derived EPCs, and urine-derived UDCs using GMP-compatible reagents (NutriStem medium, iMatrix-511 recombinant laminin). These protocols generate GMP-compatible stem cells without the use of feeders, conditioned medium, additional small molecules or proteins, or passaging during reprogramming.READ MORE